The new tuberculosis vaccine passes the first tests

Safe, effective and above all thermostable. It can therefore be easily transported, stored and administered even in those countries that are difficult to reach and with little health infrastructure. The new experimental vaccine against tuberculosis, developed thanks to the support of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, in the United States, seems very advantageous.